Teacher Retirement System of Texas Has $1.14 Million Stake in Organon & Co. (NYSE:OGN)

Teacher Retirement System of Texas grew its holdings in Organon & Co. (NYSE:OGN) by 18.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 76,264 shares of the company’s stock after purchasing an additional 11,763 shares during the quarter. Teacher Retirement System of Texas’ holdings in Organon & Co. were worth $1,138,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the business. Xponance Inc. bought a new stake in Organon & Co. during the 4th quarter worth about $179,000. Advisors Asset Management Inc. grew its stake in shares of Organon & Co. by 6.9% during the fourth quarter. Advisors Asset Management Inc. now owns 706,429 shares of the company’s stock valued at $10,540,000 after purchasing an additional 45,865 shares during the last quarter. Royce & Associates LP increased its holdings in shares of Organon & Co. by 23.7% in the fourth quarter. Royce & Associates LP now owns 869,394 shares of the company’s stock valued at $12,971,000 after purchasing an additional 166,300 shares in the last quarter. Vestcor Inc acquired a new stake in shares of Organon & Co. in the fourth quarter valued at approximately $321,000. Finally, Swiss National Bank raised its position in Organon & Co. by 0.9% in the 4th quarter. Swiss National Bank now owns 506,375 shares of the company’s stock worth $7,555,000 after purchasing an additional 4,500 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Trading Down 0.3 %

NYSE OGN opened at $14.52 on Friday. Organon & Co. has a 12 month low of $13.87 and a 12 month high of $23.10. The stock has a 50-day simple moving average of $15.33 and a 200 day simple moving average of $16.24. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The company has a market capitalization of $3.74 billion, a PE ratio of 4.36, a P/E/G ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. Research analysts forecast that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were given a dividend of $0.28 per share. The ex-dividend date was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.72%. Organon & Co.’s dividend payout ratio is 33.63%.

Analyst Ratings Changes

OGN has been the subject of several research reports. Barclays lowered their target price on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. TD Cowen upgraded Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. Finally, Morgan Stanley cut their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.